Key result
Metabolic syndrome linked to ~96 mg/dL higher fasting triglycerides compared to healthy controls.
Why the study?
Although metabolic syndrome includes abnormal blood lipids that increase the risk of heart disease and diabetes, the specific pattern and severity of these lipid changes needed further clarification.
Case-Control (n=200)
No
Markedly elevated triglycerides are the most prominent lipid abnormality differentiating patients with Metabolic Syndrome from healthy controls, explaining 96.7% of the between-group variance, whereas HDL-C levels did not significantly differ.
Hypertriglyceridemia marks metabolic syndrome in this case-control study; leaves open its causal role and utility for risk stratification pending prospective data.
Background: Metabolic syndrome (MetS) is a common condition that includes abnormal blood lipids, increasing the risk of heart disease and diabetes.However, the pattern and severity of lipid changes in MetS patients need further clarification.Aim: This study aimed to compare the lipid profile of patients with MetS against healthy controls and identify which lipid abnormality is most prominent.Methods: A case-control study enrolled 100 MetS patients (diagnosed by NCEP-ATP III criteria) and 100 age-matched healthy controls.Fasting blood samples were tested for total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C).Differences between groups were analyzed using standard statistical tests.Results: Compared to healthy controls, MetS patients had significantly higher TC (184.73 vs. 172.58mg/dL, p<0.0001),TG (219.71 vs. 123.49mg/dL, p<0.0001), and LDL-C (107.97 vs. 93.62mg/dL, p<0.0001).HDL-C levels were similar between groups (40.98 vs. 41.75 mg/dL, p=0.385).The most important finding was a significantly higher triglyceride level in MetS patients.Conclusion: Markedly elevated triglycerides are the most characteristic lipid abnormality in Metabolic Syndrome.Routine triglyceride measurement can help detect MetS early.Treatment should focus on lowering triglycerides along with managing total and LDL cholesterol.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a case-control in Metabolic Syndrome (n=200). Metabolic Syndrome vs. Healthy controls was evaluated on Fasting serum triglycerides (mg/dL) (MD +96.22 mg/dL (Cohen's d +10.71), 95% CI 93.72 to 98.73, p=<0.0001). Metabolic Syndrome patients had markedly elevated triglyceride levels compared to healthy controls (219.71 vs 123.49 mg/dL; MD +96.22 mg/dL, p<0.0001), explaining 96.7% of between-group variance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: